Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

May 16, 2018

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

peripheral blood lymphocyte therapy

DRUG

fludarabine phosphate

DRUG

methylprednisolone

DRUG

thiotepa

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

RADIATION

total-body irradiation

Trial Locations (6)

32610

University of Florida Health Science Center - Gainesville, Gainesville

90027-0700

Childrens Hospital Los Angeles, Los Angeles

02114

Massachusetts General Hospital, Boston

02115

Children's Hospital Boston, Boston

Dana Farber Cancer Institute, Boston

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00376480 - Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter